Distribuzione geografica
Continente #
NA - Nord America 19068
EU - Europa 4814
AS - Asia 2151
AF - Africa 123
SA - Sud America 23
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26196
Nazione #
US - Stati Uniti d'America 18501
CN - Cina 1507
SE - Svezia 1159
BG - Bulgaria 1032
IT - Italia 765
CA - Canada 566
DE - Germania 430
UA - Ucraina 421
VN - Vietnam 394
GB - Regno Unito 227
FI - Finlandia 206
FR - Francia 170
AT - Austria 144
TR - Turchia 123
RU - Federazione Russa 117
CI - Costa d'Avorio 67
BE - Belgio 43
IN - India 34
NL - Olanda 21
SN - Senegal 20
RO - Romania 17
JP - Giappone 14
BR - Brasile 12
PK - Pakistan 12
AU - Australia 10
KR - Corea 10
ES - Italia 9
GR - Grecia 9
HK - Hong Kong 9
CZ - Repubblica Ceca 8
EG - Egitto 8
IR - Iran 8
NG - Nigeria 8
CH - Svizzera 7
ET - Etiopia 7
HU - Ungheria 6
ID - Indonesia 6
CL - Cile 5
EU - Europa 5
IQ - Iraq 5
SG - Singapore 5
TW - Taiwan 5
DK - Danimarca 4
IE - Irlanda 4
MR - Mauritania 4
PE - Perù 4
TH - Thailandia 4
MD - Moldavia 3
MY - Malesia 3
PL - Polonia 3
AR - Argentina 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
IL - Israele 2
KE - Kenya 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BN - Brunei Darussalam 1
DZ - Algeria 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MX - Messico 1
UG - Uganda 1
Totale 26196
Città #
Fairfield 3080
Woodbridge 3041
Ann Arbor 1791
Houston 1744
Seattle 1207
Ashburn 1180
Sofia 1032
Cambridge 1007
Wilmington 965
Chandler 928
Beijing 567
Jacksonville 564
Ottawa 554
Princeton 438
Lawrence 428
Medford 352
Des Moines 328
Nanjing 272
San Diego 166
Dearborn 160
Dong Ket 151
Vienna 130
Frankfurt am Main 129
Nanchang 122
Izmir 103
Jüchen 99
Serra 87
Kunming 78
Abidjan 66
Shenyang 64
Changsha 63
Florence 58
Hefei 56
Hebei 49
Redwood City 48
Jiaxing 41
Boulder 40
Brussels 40
Tianjin 40
London 39
Norwalk 39
Pisa 37
Milan 30
Jinan 26
Lancaster 24
Dakar 20
Falls Church 20
Bremen 18
Verona 16
Boardman 15
Orange 15
Lucca 13
Auburn Hills 12
Guangzhou 12
Hangzhou 11
Los Angeles 11
Xian 11
Marseille 10
Paris 9
San Francisco 9
Shanghai 9
Chengdu 8
Prague 8
Redmond 8
Changchun 7
Düsseldorf 7
Detroit 6
Indiana 6
Lagos 6
New York 6
Simi Valley 6
Bucharest 5
Budapest 5
Cairo 5
Chicago 5
Edinburgh 5
Haikou 5
Lanzhou 5
Nürnberg 5
Phoenix 5
Taipei 5
Zhengzhou 5
Chaoyang 4
Chongqing 4
Dallas 4
Dublin 4
Fort Worth 4
Jakarta 4
Lima 4
Madrid 4
Munich 4
Ningbo 4
Rome 4
Singapore 4
Torino 4
Toronto 4
Vicopisano 4
Wenzhou 4
Wuhan 4
Casale Monferrato 3
Totale 21868
Nome #
Active HBV replication in HBsAg carriers with chronic Delta infection 152
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound 149
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 143
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen 132
Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen 132
Sequence variation in hepatitis C viral isolates 132
Development of a liver model using PAM scaffolds in static and dynamic conditions 132
A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers 132
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study 131
Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D 125
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B 124
Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? 123
A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease 122
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview 119
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 116
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 116
Hepatitis delta virus, a model of liver cell pathology 115
Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization 115
High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders 115
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations 114
Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects 114
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 114
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 112
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values 111
A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients 111
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment 111
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 111
Software and expert system for the management of chronic hepatitis B 110
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 110
T-lymphocyte response to hepatitis C virus in different clinical courses of infection 109
Hepatitis B virus unable to secrete e antigen 108
Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children 108
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients 108
Variants of hepatitis B virus 107
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C 107
Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay 106
Possible immunopathogenesis for fibrosing cholestatic hepatitis 105
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? 105
Validation and comparison of different PCR-based methods for detection of Hepatitis B virus precore region mutants 105
Hepatitis C virus infection in type II essential mixed cryoglobulinemias 103
Problems in diagnosing viral hepatitis 103
Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay 102
Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences 102
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 102
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 102
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 101
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier 101
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 100
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging 100
The natural history of chronic delta hepatitis 98
Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B 98
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy 98
A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combin 98
The role of quantitative hepatitis B surface antigen revisited 97
Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen 97
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care' 96
Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. 96
null 96
Laparoscopic robot-assisted distal splenorenal shunt 96
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin 95
null 95
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer 94
Diagnostic markers of chronic hepatitis B infection and disease” 94
The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue 94
'e' antigen defective hepatitis B virus and course of chronic infection 94
Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies 93
null 93
null 93
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy 93
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study 92
Potential applications of extracorporeal photopheresis in liver transplantation 92
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 92
AISF position paper on HCV in immunocompromised patients. 92
Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study 91
null 91
null 91
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 90
New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases 90
Role of hepatitis delta virus infection in hepatocellular carcinoma 89
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C 89
Uridine diphosphate glucoronosyl transferases, candidate antigens of liver-kidney microsomal antibodies in hepatitis delta virus-infected patients 88
Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features 88
Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? 88
A multiphase model of th dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alfa2a, lamivudine and combination therapy 88
Asymptomatic hypermylasemia and hyperlipasemia associated with aripiprazole 88
Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study 88
null 88
Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. 88
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. 87
Hepatitis B virus surface antigen levels: a guide to sustained response to Peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 87
null 87
A new hepatitis C virus-like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatise serum levels 87
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study 87
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study 86
Does HBeAg minus HBV modify the course of HDV superinfection? 85
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection 85
Recurrence of hepatitis B after liver transplantation is associated with intrahepatic HBcAg and serum IgM anti-HBc 85
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection 84
Totale 10316
Categoria #
all - tutte 47332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47332

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018281 0000 00 00 0026021
2018/20194098 302595 23632 90241 426691188919
2019/20207045 1020597212480 764778 769638 757431486113
2020/20212917 275157204159 194123 202236 356234220557
2021/20224366 13027273269 776676 171200 2442121591184
2022/20233217 610314202245 336453 54247 540321840
Totale 26696